New Protein Discovery Offers Hope for Preventing Diabetic Blindness
A groundbreaking discovery by researchers at University College London (UCL) offers a potential turning point in the fight against diabetic retinopathy, a leading cause of vision loss among working-age adults. The research, published in Science Translational Medicine, identifies a protein called LRG1 as a key trigger in the early stages of this debilitating eye disease.
Understanding Diabetic Retinopathy
Diabetic retinopathy affects individuals with both type 1 and type 2 diabetes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Currently, treatment typically begins once symptoms like blurred or distorted vision appear, at which point irreversible damage may have already occurred. Existing therapies, which target a protein called VEGF, are effective for only about 50% of patients and rarely reverse existing harm. UCL News
The Role of LRG1
The UCL-led research team found that LRG1 causes the cells surrounding the eye’s smallest blood vessels to constrict excessively, effectively “squeezing” them. This constriction reduces oxygen supply to the retina, initiating a chain of events that can lead to long-term vision impairment. Diabetes UK
Blocking LRG1: A Potential Breakthrough
In experiments using mouse models of diabetes, researchers were able to block the activity of LRG1 and prevent the early stages of retinal damage, preserving healthy eye function. This suggests that targeting LRG1 could offer a way to protect vision before serious damage occurs and potentially prevent blindness in millions of people living with diabetes. ScienceDaily
“Our discovery shows that diabetic eye disease starts earlier than we thought, and LRG1 is a key culprit in this early damage,” said Dr. Giulia De Rossi of the UCL Institute of Ophthalmology, lead author of the study. UCL News
A New Therapeutic Approach
Researchers have already developed a drug designed to target LRG1. The treatment has undergone initial testing and is currently in the preclinical research phase, with the potential to move into human clinical trials in the near future. Scientists believe this therapy could not only prevent the development of diabetic retinopathy but too benefit those with more advanced disease, as LRG1 continues to contribute to damage at later stages. News USA Today
Collaboration and Funding
This research was supported by funding from Diabetes UK, Moorfields Eye Charity, and Wellcome. Dr. Faye Riley, research communications lead at Diabetes UK, commented, “By identifying the root cause of early damage, and offering a new path for treatment, this research holds immense promise for protecting the sight of the growing number of people with diabetes worldwide.” Diabetes UK
Looking Ahead
The discovery of LRG1’s role in diabetic retinopathy represents a significant step forward in the prevention and treatment of this sight-threatening condition. As the LRG1-targeting therapy progresses through clinical trials, it offers renewed hope for protecting the vision of millions affected by diabetes. ScienceDaily